Zecotek Receives United States Patent Allowance for its MAPD Solid-State Photo Detector
Singapore, February 19, 2014 – Zecotek Photonics Inc. (TSX-V: ZMS; Frankfurt: W1I), a developer of leading-edge photonics technologies for medical, industrial and scientific markets, today announced that the United States Patent Office has issued a Notice of Allowance for its Micro-channel Avalanche Photodiode (MAPD) solid-state photo detector. The Company is focused on strengthening its patent portfolio specific to imaging technology and associated components, and this patent allowance represents another important step is securing intellectual property related to all key elements for a high performance PET scanner.
“The US patent allowance for our MAPD solid-state photo-detector is important to our strategic alliance with Hamamatsu Photonics and our relationship with the prestigious science institution CERN,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “The MAPD solid-state photo detector is a key alternative component for the development of a new generation PET scanner, and having protection of the underlying MAPDtechnology is very important to our Company and our shareholders. The MAPD is now patented in the United States, Russia, Japan, South Korea, Singapore and China, and patents are pending in other countries. We will continue to be vigilant with respect to the security of our technologies patent portfolio.”
Zecotek’s proprietary MAPD-3N is a design upgrade of the previously announced MAPD. It offers significant performance-cost advantages over competing photomultiplier tubes (PMT) and other solid-state, silicon based photo-detectors. Its good recovery time, unique radiation hardness and display of the highest possible linearity make it a prime component for the improved detector designs required in the next crucial phase of high energy experiments at CERN. Its low manufacturing cost, excellent timing resolution and Photon Detection Efficiency are key characteristics for the new configurations of high resolution PET (Positron Emission Tomography) scanners.
The MAPD-3N is supplied to customers through Zecotek Imaging Systems Pte. Ltd., Singapore, a wholly owned subsidiary of Zecotek Photonics Inc., and manufactured under contract by the National NanoFab Center, Daejeon City, South Korea.
Zecotek Photonics Inc (TSX-V: ZMS; Frankfurt: W1I) is a photonics technology company developing high-performance scintillation crystals, photo detectors, positron emission tomography scanning technologies, 3D auto-stereoscopic displays, and lasers for applications in medical, high-tech and industrial sectors. Founded in 2004, Zecotek operates three divisions: Imaging Systems, Laser Systems and 3D Display Systems with labs located in Canada, Korea, Russia, Singapore and U.S.A. The management team is focused on building shareholder value by commercializing over 50 patented and patent pending novel photonic technologies directly and through strategic alliances and joint ventures with leading industry partners such as Hamamatsu Photonics (Japan), the European Organization for Nuclear Research (Switzerland), Beijing Opto-Electronics Technology Co. Ltd. (China), NuCare Medical Systems (South Korea), and National NanoFab Center (South Korea). For more information visit Zecotek Photonics, follow @zecotek on Twitter and “like” us in Facebook.
This press release may contain forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what may have been stated.
For Additional Information Please Contact:
Zecotek Photonics Inc.
T: (604) 783-8291
The TSX Venture 50® are the top 10 companies listed on the TSX Venture Exchange, in each of five major industry sectors – mining, oil & gas, technology & life sciences, diversified industries and clean technology – based on a ranking formula with equal weighting given to return on investment, market cap growth, trading volume and analyst coverage. All data was as of December 31, 2013.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the content of this news release. If you would like to receive news from Zecotek in the future please visit the corporate website at www.zecotek.com.